Clinical Trials Logo

Clinical Trial Summary

Recent studies have established the reliability, validity and time course of the cannabis withdrawal syndrome. This study will investigate the effects of combined treatment of Escitalopram with cognitive-behavior therapy in alleviating the symptoms of the marijuana withdrawal syndrome in regular chronic users of marijuana. We predict that combined pharmacological treatment and cognitive-behavior therapy will help patients to abstain from using using marijuana and it will alleviate their marijuana withdrawal symptoms.


Clinical Trial Description

Recent studies have established the reliability, validity and time course of the cannabis withdrawal syndrome characterized by symptoms of anxiety, irritability, negative mood, physical symptoms and decreased appetite. This study will investigate the effects of combined treatment of Escitalopram with cognitive-behavior therapy in alleviating the symptoms of the marijuana withdrawal syndrome in regular chronic users of marijuana. 40 patients will be blindly randomized to either active or placebo escitalopram 10mg/day, for 12 weeks followed bt 12 weeks of follow-up.

Inclusion criteria include:

- Men and women age 20-45

- DSM-IV diagnosis of THC dependence.

Exclusion criteria include:

- Dependence on other drugs or alcohol

- Bipolar Disorder or Schizophrenia, Major depression, suicidal ideation psychotic symptoms or violent thoughts

- Current treatment with anti-depressant medication

- Neurological disease

- Physical illness (hypothyroidism, severe anemia, renal failure)

- Past severe effects of SSRIs.

Outcome measures include:

- urine THC analysis every two weeks

- questionnaires assessing addiction severity index

- depression and anxiety. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00598052
Study type Interventional
Source Tel-Aviv Sourasky Medical Center
Contact Aviv M Weinstein, Ph.D
Phone 97236973685
Email avivmw@tasmc.health.gov.il
Status Recruiting
Phase N/A
Start date December 2007
Completion date October 2008

See also
  Status Clinical Trial Phase
Active, not recruiting NCT00875836 - Buspirone Treatment for Marijuana Dependence Phase 4
Completed NCT00893269 - The Effect of Marijuana and Prescription Medications in Mood, Performance and Sleep Phase 1
Completed NCT00490269 - Ph1 Marinol Interaction Study - Part 2 - 1 Phase 1
Completed NCT02579421 - Hormones and Reduction in Co-users of Marijuana and Nicotine N/A
Terminated NCT01598896 - Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia Phase 2/Phase 3
Completed NCT00373295 - Effect of Baclofen on Marijuana Withdrawal and Relapse Phase 2
Active, not recruiting NCT01827332 - Effect of Oxytocin on Craving and Therapy Response N/A
Completed NCT01335789 - Effect of Oxytocin on Stress in Marijuana Users N/A
Terminated NCT00438139 - Ph1 Marinol Interaction Study - Part 1 - 1 Phase 1
Completed NCT02955329 - Vaping THC From Electronic Cigarettes Phase 3
Completed NCT02439814 - Pregnenolone and Marijuana Dependence Phase 2
Completed NCT01039415 - Attempts to Stop/Reduce Marijuana Among Dependent Users N/A
Completed NCT01347762 - Nabilone for Cannabis Dependence: A Pilot Study Phase 2/Phase 3
Completed NCT00270803 - The Effects of Marijuana on Orientation and Motor Coordination and Brain Metabolism in Regular Smokers of Marijuana N/A
Completed NCT01020019 - Combined Pharmacotherapy for Cannabis Dependency Phase 2/Phase 3
Completed NCT02030665 - Marijuana Treatment Project 4 N/A
Completed NCT00107588 - Marijuana Treatment Project - 3 N/A
Completed NCT02011516 - Baclofen Effects on Marijuana Dependence Phase 2
Completed NCT00350649 - Maximizing the Efficacy of Cognitive Behavior Therapy and Contingency Management Phase 2
Completed NCT00374127 - Comparison Between Marijuana Smoked in Cigarette Paper Versus Cigar Paper Phase 2